VERTEX PHARMACEUTICALS INC / MA Cash Flow Hedge Derivative Instrument Assets at Fair Value
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Cash Flow Hedge Derivative Instrument Assets at Fair Value of $6.20 million as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes
us-gaap:CashFlowHedgeDerivativeInstrumentAssetsAtFairValue · last filed 2026-02-13
- 2025-12-31: Cash Flow Hedge Derivative Instrument Assets at Fair Value $6.20M.
- 2024-12-31: Cash Flow Hedge Derivative Instrument Assets at Fair Value $130.10M.
- 2023-12-31: Cash Flow Hedge Derivative Instrument Assets at Fair Value $1.80M.
- 2022-12-31: Cash Flow Hedge Derivative Instrument Assets at Fair Value $47.50M.
| Period end | Cash Flow Hedge Derivative Instrument Assets at Fair Value |
|---|---|
| 2025-12-31 | $6.20M 10-K · filed 2026-02-13 |
| 2024-12-31 | $130.10M 10-K · filed 2026-02-13 |
| 2023-12-31 | $1.80M 10-K · filed 2025-02-13 |
| 2022-12-31 | $47.50M 10-K · filed 2024-02-15 |
| 2021-12-31 | $44.50M 10-K · filed 2023-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |